Safety and Immunogenicity of the RNA MCTI CIMATEC HDT Vaccine

NCT ID: NCT05542693

Last Updated: 2022-09-15

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 300 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-01-31
• Study Completion Date: 2023-09-30

Brief Summary

A multicenter, randomized, double-blind, active comparator, non-inferiority, multicenter IIb clinical trial to compare the safety and immunogenicity of two dose levels of the MCTI CIMATEC HDT RNA Vaccine against two authorized COVID-19 vaccines in Brazil (Comirnaty - Pfizer and Covishield - Oxford/AstraZeneca) in 300 participants. Each vaccine will be provided as a single booster vaccine in adults aged 18 to 65 years previously immunized with both vaccines (Comirnaty - Pfizer and Covishield - Oxford/Astrazen). The investigational product MCTI C HDT will be administered in one of the two doses evaluated (5µg and 10 µg). The comparator products will be Comirnaty - Pfizer and Covishield - Oxford/AstraZeneca. The primary outcomes will be the number of participants with a 2-fold increase or more on average by titers of neutralizing D64G pseudovirus strain (pNT50) and comparison of titers generated by 5µg and 10µg doses of MCTI-CIMATEC-HDT RNA Vaccine.

Conditions

COVID-19; COVID-19 Vaccine

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: DOUBLE

Study Groups

RNA MCTI CIMATEC HDT 5µg

Intramuscular injections of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT) at a dose of 5 µg of single-dose administration on day 1.

Group Type: EXPERIMENTAL

RNA MCTI CIMATEC HDT 5µg

Intervention Type: BIOLOGICAL

Adults previously immunized will be randomized to receive a single booster vaccine: experimental (MCTI-CIMATEC-HDT RNA)

RNA MCTI CIMATEC HDT 10µg

Intramuscular injections of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT) at a dose of 10 µg of single-dose administration on day 1.

Group Type: EXPERIMENTAL

RNA MCTI CIMATEC HDT 10µg

Intervention Type: BIOLOGICAL

Adults previously immunized will be randomized to receive a single booster vaccine: experimental (MCTI-CIMATEC-HDT RNA)

Covishield® - AstraZeneca

Intramuscular injections of vaccine Covishield® - AstraZeneca at a usual dose of single-dose administration on day 1.

Group Type: ACTIVE_COMPARATOR

Covishield® - AstraZeneca

Intervention Type: BIOLOGICAL

Adults previously immunized will be randomized to receive a single booster vaccine comparator (Comirnaty - Pfizer)

Comirnaty® - Pfizer

Intramuscular injections of vaccine Comirnaty® - Pfizer at a usual dose of single-dose administration on day 1.

Group Type: ACTIVE_COMPARATOR

Comirnaty® - Pfizer

Intervention Type: BIOLOGICAL

Adults previously immunized will be randomized to receive a single booster vaccine comparator (Comirnaty - Pfizer and (Covishield - Oxford/Astrazen).

Interventions

RNA MCTI CIMATEC HDT 5µg

Adults previously immunized will be randomized to receive a single booster vaccine: experimental (MCTI-CIMATEC-HDT RNA)

Intervention Type: BIOLOGICAL

RNA MCTI CIMATEC HDT 10µg

Adults previously immunized will be randomized to receive a single booster vaccine: experimental (MCTI-CIMATEC-HDT RNA)

Intervention Type: BIOLOGICAL

Covishield® - AstraZeneca

Adults previously immunized will be randomized to receive a single booster vaccine comparator (Comirnaty - Pfizer)

Intervention Type: BIOLOGICAL

Comirnaty® - Pfizer

Adults previously immunized will be randomized to receive a single booster vaccine comparator (Comirnaty - Pfizer and (Covishield - Oxford/Astrazen).

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Age ≥ 18 years

2. Complete primary vaccination with Cominarty (Pfizer) or Covishield (Oxford/Astrazeneca) vaccines, and at least one booster dose with Cominarty (Pfizer) or Covishield (Oxford/Astrazeneca) vaccines. The last duration being at least 4 before the study duration.

3. Adult in a healthy condition or with a stable health status if pre-existing medical history.

4. Sign informed consent, be able and willing to make the assessment, be accessible by telephone or in person by the local study team and willing to remain in the study area for the duration of the study

5. For women of childbearing age: a highly negative sensitive urinary pregnancy test during the inclusion visit AND use an effective contraceptive method.

Exclusion Criteria

1. History of COVID-19 in the 30 days before study enrollment.

2. Participation in other clinical studies in the last 12 (two) months.

3. Receive or plan any immunization during the study, except the seasonal influenza vaccine, within 30 days of enrollment.

4. Receive a blood or immunoglobulin transfusion within 90 days before study enrollment;

5. Blood donation up to 30 days before inclusion in the study;

6. Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immunomodulatory drugs.

7. History of autoimmune disease or immunosuppression.

8. Rash, tattoos, or any other skin condition that could adversely affect the vaccine injection site.

9. Body mass index (BMI) > 35.

10. Known or suspected drug or alcohol abuse in the last 6 months;

11. History of previous anaphylaxis or severe allergic reactions to the vaccine, products known to contain polyethene glycol (PEG) or unknown allergens.

12. History of myocarditis or carditis.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

SENAI CIMATEC

OTHER

Sponsor Role: collaborator

Azidus Brasil

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

RNA-MCTI-CIMATEC-HDT-002

Identifier Type: -

Identifier Source: org_study_id